FWM
TMO icon

Frontier Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History

Frontier Wealth Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$10M Sell
18,414
-161
-0.9% -$88.6K 0.73% 29
2022
Q1 		$10.6M Buy
18,575
+45
+0.2% +$25.9K 0.13% 30
2021
Q4 		$12.4M Sell
18,530
-1,030
-5% -$643K 0.82% 26
2021
Q3 		$11.2M Sell
19,560
-1,975
-9% -$1.08M 0.77% 26
2021
Q2 		$10.9M Buy
21,535
+349
+2% +$165K 0.76% 24
2021
Q1 		$9.67M Sell
21,186
-44
-0.2% -$21K 0.74% 25
2020
Q4 		$9.89M Sell
21,230
-40
-0.2% -$18.8K 0.81% 22
2020
Q3 		$9.39M Hold
21,270
– – 0.86% 22
2020
Q2 		$7.71M Sell
21,270
-110
-0.5% -$36.9K 0.71% 30
2020
Q1 		$6.06M Buy
21,380
+3,672
+21% +$1.16M 0.99% 27
2019
Q4 		$5.75M Sell
17,708
-3,889
-18% -$1.18M 0.92% 23
2019
Q3 		$6.29M Sell
21,597
-3,341
-13% -$957K 0.93% 25
2019
Q2 		$7.32M Buy
24,938
+3,563
+17% +$981K 1.08% 22
2019
Q1 		$5.85M Sell
21,375
-344
-2% -$85.6K 0.79% 28
2018
Q4 		$4.86M Buy
21,719
+23
+0.1% +$5.4K 0.74% 27
2018
Q3 		$5.3M Buy
21,696
+311
+1% +$71.5K 0.51% 25
2018
Q2 		$4.43M Sell
21,385
-862
-4% -$183K 0.63% 35
2018
Q1 		$4.59M Buy
22,247
+9,339
+72% +$1.96M 0.64% 38
2017
Q4 		$2.45M Sell
12,908
-7,543
-37% -$1.45M 0.39% 62
2017
Q3 		$3.87M Buy
20,451
+130
+0.6% +$23.5K 0.56% 46
2017
Q2 		$3.54M Buy
20,321
+210
+1% +$35.3K 0.54% 49
2017
Q1 		$3.09M Sell
20,111
-69
-0.3% -$10.5K 0.47% 58
2016
Q4 		$2.85M Sell
20,180
-485
-2% -$71.5K 0.47% 62
2016
Q3 		$3.29M Hold
20,665
– – 0.5% 47
2016
Q2 		$3.05M Sell
20,665
-1,240
-6% -$183K 0.49% 47
2016
Q1 		$3.1M Buy
21,905
+161
+0.7% +$21.6K 0.26% 50
2015
Q4 		$3.08M Buy
21,744
+2,210
+11% +$295K 0.5% 51
2015
Q3 		$2.39M Buy
19,534
+2,184
+13% +$285K 0.38% 69
2015
Q2 		$2.25M Buy
17,350
+7,000
+68% +$913K 0.35% 66
2015
Q1 		$1.39M Buy
10,350
+7,000
+209% +$902K 0.22% 83
2014
Q4 		$420K Buy
+3,350
New +$407K 0.08% 160

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frontier Wealth Management's TMO Position: Q2 2022 in Review

Frontier Wealth Management reduced its Thermo Fisher Scientific (TMO) stake by 0.87% in Q2 2022, selling an estimated $88.6K and leaving 18,414 shares worth $10M. The position accounts for 0.73% of the portfolio, ranked #29.

Frontier Wealth Management first reported a position in TMO in Q4 2014 and has held it in 31 quarters since. The position peaked at $12.4M in Q4 2021. 2,283 funds tracked by Wall St. Rank hold TMO as of Q2 2022.

  • Frontier Wealth Management held 18,414 shares of Thermo Fisher Scientific worth $10M as of Q2 2022.
  • Frontier Wealth Management sold 161 Thermo Fisher Scientific shares in Q2 2022, an estimated $88.6K.
  • Thermo Fisher Scientific made up 0.73% of Frontier Wealth Management's portfolio in Q2 2022, its #29 holding.
  • Frontier Wealth Management first reported a position in Thermo Fisher Scientific in Q4 2014 and has held it in 31 quarters since.
  • Frontier Wealth Management's Thermo Fisher Scientific position peaked at $12.4M in Q4 2021.
  • 2,283 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.